EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)

Diagnostic Performance of the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors

Christian Uprimny, Elisabeth von Guggenberg, Anna Sviridenko, Steffen Bayerschmidt, Lisa Maria Rossetti, Hessamoddin Roustaei, Boris Warwitz, Hanno Ulmer, Angelika Hutter, Gianpaolo di Santo, Irene J Virgolini

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.125.269863 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Christian Uprimny und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Thyroid Neoplasms, Neuroendocrine Tumors, Gallium Radioisotopes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A prospective phase 1/2a pilot study (NCT06155994) was performed at our center to compare the diagnostic performance of cholecystokinin-2 receptor (CCK2R) PET/CT imaging with the 68Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH2 (68Ga-DOTA-MGS5) with that of the reference standard PET/CT.

Methods

Six patients with advanced medullary thyroid cancer (MTC) and 6 patients with other neuroendocrine tumors (NETs)-4 with gastroenteropancreatic (GEP) NETs and 2 with bronchopulmonary (BP) NETs-were included in the study. All patients had known metastases, documented by 68Ga-DOTATOC and 18F-DOPA PET/CT. Intensity of tracer accumulation (SUVmax/SUVmean) of normal tissue and lesions judged malignant was compared with standard PET imaging (number of lesions, uptake per lesion).

Results

When compared with standard imaging, 68Ga-DOTA-MGS5 showed significantly increased blood-pool activity (P ≤ 0.009), with improved lesion contrast at 2 h after injection compared with 1 h after injection. Four of 6 patients with MTC had positive lesions on 68Ga-DOTA-MGS5 PET/CT. Fifty-one lesions were detected with 18F-DOPA versus 48 with 68Ga-DOTA-MGS5, with a significantly higher mean SUVmax of 7.2 at 1 h and 2 h after injection versus 4.7 with 18F-DOPA (P 0.5). In patients with non-MTC NETs, 26 CCK2R-positive lesions were confirmed for 2 patients with BP-NETs compared with 45 lesions visualized with 68Ga-DOTATOC. In the 4 patients with GEP-NETs, only 1 of 21 lesions displaying positive uptake on 68Ga-DOTATOC PET/CT was visualized with 68Ga-DOTA-MGS5 (an ileal NET), whereas the lesions in the other 3 patients were negative on 68Ga-DOTA-MGS5 PET/CT.

Conclusion

CCK2R PET/CT using 68Ga-DOTA-MGS5 showed a high tumor lesion detection rate in patients with MTC, with lesion uptake values comparable to those with 18F-DOPA and 68Ga-DOTATOC. In patients with non-MTC NETs, 68Ga-DOTA-MGS5 PET/CT showed possible applicability in patients with BP-NETs, which needs to be verified in a larger patient cohort. In contrast, 68Ga-DOTA-MGS5 PET/CT seemed to be of limited value in patients with GEP-NETs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyThyroid NeoplasmsNeuroendocrine TumorsGallium RadioisotopesCarcinoma, NeuroendocrineGastrinsOrganometallic CompoundsHumansMaleFemaleMiddle AgedAgedAdultPilot Projects

Stichwörter der Autor:innen

68GaPETcholecystokinin-2 receptormedullary thyroid cancerminigastrinneuroendocrine tumors

Substanzen

Gallium RadioisotopesGastrinsminigastrinOrganometallic Compounds

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Nuclear Medicine, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria; and.
  • Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; elisabeth.von-guggenberg@i-med.ac.at.
  • Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, Innsbruck, Austria.

Zitieren

APA

Uprimny, C., von Guggenberg, E., Sviridenko, A., Bayerschmidt, S., Rossetti, L. M., Roustaei, H., Warwitz, B., Ulmer, H., Hutter, A., di Santo, G., & Virgolini, I. J. (2025). Diagnostic Performance of the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.269863

Vancouver

Uprimny C, von Guggenberg E, Sviridenko A, Bayerschmidt S, Rossetti LM, Roustaei H, et al. Diagnostic Performance of the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.269863

BibTeX
@article{Uprimny2025,
  author = {Uprimny, Christian and von Guggenberg, Elisabeth and Sviridenko, Anna and Bayerschmidt, Steffen and Rossetti, Lisa Maria and Roustaei, Hessamoddin and Warwitz, Boris and Ulmer, Hanno and Hutter, Angelika and di Santo, Gianpaolo and Virgolini, Irene J},
  title = {Diagnostic Performance of the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.125.269863}
}
Kostenlos starten →